Perjeta, also known as pertuzumab, is a important advancement in addressing HER2-positive mammary cancer. It works by targeting a specific pathway that helps cancer cells grow . In contrast to some other HER2-targeted therapies, pertuzumab doesn't directly block the HER2 receptor itself, but instead